Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Top 10 News for 5/18 - 5/22: Fed Rate Hike Pushed Back; Icahn Calls for More Apple Buybacks; Big Banks Settle FX Probe
- Yellen Says Rate Hike at Some Point This Year 'Appropriate'
- Deere & Co. (DE) Posts Q2 EPS of $2.03; Lowers Equipment Sales Outlook for FY15
- Hewlett-Packard (HPQ) Tops Q2 EPS by 1c; Guides Q3 EPS to Low-Side of Expectations
- Foot Locker (FL) Tops Q1 EPS by 7c
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pluristem Issues Letter to Shareholders
- Pluristem Therapeutics' (PSTI) PLX Cells Selected for EMA Adaptive Pathways Pilot Project
- Cerulean Pharma (CERU) granted Orphan Drug Designations for treatment of ovarian cancer
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!